🔎 Trials Near Me

Home › Dementia › NCT06147999

Impact of a Biophoton Therapy on Patients With Brain Disorders

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Must meet conditions for approval.
* Must be 18-years or older and stay in a hotel.
* Must have a caregiver willing to support the participant's full involvement in the study. • The caregiver can assist in completing all study surveys.
* Can provide informed consent or can be assisted by caregiver.
* Can provide a clinical diagnosis of a brain disorder.
* Can complete all study procedures during the study.
* Must be fluent in English (or the Caregiver can fully translate).
* Women of childbearing age must provide results of a pregnancy test in order to participate.

Exclusion Criteria:

* Any untreated mental illnesses, that would affect study participation. This will be judged by the caregiver, or by the clinical study medical expert.
* Someone that relies on a ventilator.
* Someone who has a deep brain stimulator, pacemaker, or any implanted electronic devices.
* Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.
* Is participating in another investigational drug or device trial.
* Has an active infectious disease, such as COVID-19.
* Pregnant women.

About the study

Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, Parkinson's disease) will participate in the intervention clinical study at the Tesla MedBed Center located in Butler, PA.

What is being tested

Sponsor: First Institute of All Medicines · Participants: 80 · Started: Nov 8, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT06147999

Locations in the U.S.

PennsylvaniaTesla MedBed Center, 139 Pittsburgh Road, Butler, PA 16001, Butler

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.